Nonscarring Inflammatory Alopecia Associated With the Epidermal Growth Factor Receptor Inhibitor Gefitinib
August 2006
in “
Journal of the American Academy of Dermatology
”
Studysummary This case report describes a woman who developed extensive nonscarring inflammatory hair loss after two years of gefitinib treatment, highlighting potential cutaneous side effects associated with epidermal growth factor receptor blockers.
Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
Read the full study on jaad.org →